Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present SIGA Technologies, Inc. (NASDAQ: SIGA).

Full DD Report for SIGA

You must become a subscriber to view this report.


Recent News from (NASDAQ: SIGA)

SIGA Announces Priority Review Voucher Transaction Totaling $80 Million
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into an agreement to sell its medical countermeasures priority review voucher (PRV)...
Source: GlobeNewswire
Date: November, 01 2018 07:30
SIGA Technologies: Undervalued After Receiving A Large Government Contract
Editor's note: Seeking Alpha is proud to welcome Trevor McLemore as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » SIGA Tech...
Source: SeekingAlpha
Date: October, 10 2018 10:36
Orchestra BioMed(TM) Adds Three Industry Leaders to Strategic Advisory Board
Eric A. Rose, M.D., biotech and medical device business leader as well as world-renowned cardiac surgeon and scientist who performed the landmark achievement of the first successful pediatric heart transplant    Jason Aryeh, life sciences industry expert, investmen...
Source: GlobeNewswire
Date: October, 09 2018 12:00
SIGA inks deal with USAMRIID to evaluate the efficacy of TPOXX as a PEP for smallpox
SIGA Technologies (NASDAQ: SIGA ) has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases ((USAMRIID)). More news on: SIGA Technologies Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: October, 04 2018 08:50
SIGA Enters into Cooperative Research and Development Agreement with U.S. Army Medical Research Institute of Infectious Disease to Evaluate the Efficacy of TPOXX® as a Post-Exposure Prophylactic for Smallpox
NEW YORK, Oct. 04, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States A...
Source: GlobeNewswire
Date: October, 04 2018 07:30
SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018
- Company Hosting Business Update Webcast Today at 4:30pm ET - NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA...
Source: GlobeNewswire
Date: September, 27 2018 07:30
Key events next week for healthcare investors
Noteworthy events during the week of August 5-11 for healthcare investors. More news on: Insmed, Inc., Pain Therapeutics, Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 03 2018 07:58
Your Daily Pharma Scoop: Advaxis Trial Cleared, Atossa Trial Proceeds, Amgen Resubmits NDA
Stocks in News: ADXS, ATOS FDA lifts clinical hold on Advaxis study of axalimogene filolisbac; shares up 61% premarket Discussion : Advaxis ( ADXS ) announced lifting of hold on its Phase ½ clinical trial of axalimogene filolisbac, in combination with AstraZeneca's Imfinzi (durva...
Source: SeekingAlpha
Date: July, 16 2018 03:24
U.S. Food and Drug Administration Approves SIGA Technologies' TPOXX® (tecovirimat) for the Treatment of Smallpox
- First therapy specifically approved for smallpox advances health security against a significant bioterror threat- - Company Granted Priority Review Voucher - NEW YORK, July 13, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutic...
Source: GlobeNewswire
Date: July, 13 2018 15:47
Pivotal Trial Data for SIGA Technologies' Oral TPOXX® Published in the New England Journal of Medicine
- Results support the use of TPOXX to treat smallpox, a highly contagious and lethal virus that poses significant bioterror threat - NEW YORK, July 05, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the healt...
Source: GlobeNewswire
Date: July, 05 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-087.437.257.43547.16154,118
2018-05-186.676.626.706.57442,798
2018-05-176.676.626.706.57442,798

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0717,55935,92248.8809Short
2018-12-0612,21239,64330.8049Cover
2018-12-0417,30227,83462.1614Short
2018-12-037,03338,77318.1389Cover
2018-11-309,64235,36327.2658Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SIGA.


About SIGA Technologies, Inc. (NASDAQ: SIGA)

Logo for SIGA Technologies, Inc. (NASDAQ: SIGA)

We are a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is Tecovirimat, also known as ST , an orally administered antiviral drug that targets orthopoxviruses. While Tecovirimat is not yet licensed as safe or effective by the U.S. Food amp Drug Administration, it is a novel small molecule drug that is being delivered to the Strategic National Stockpile under Project BioShield.

 

Contact Information

 

 

Current Management

  • Phillip L Gomez / CEO
  • Daniel J. Luckshire / CFO, EVP, EVP, Fin.
  • Dennis E. Hruby / CSO
  • Robin Abrams / General Counsel
  • James J. Antal /
  • Michael J. Bayer /
  • Thomas E. Constance /
  • Joseph W. Marshall, III /
  • Jeffrey B. Kindler /
  • Michael Plansky /
  • Eric Rose /
  • Paul G. Savas /

Current Share Structure

  • Market Cap: $456,450,225 - 03/16/2018
  • Authorized: 600,000,000 - 10/10/2016
  • Issue and Outstanding: 79,039,000 - 02/28/2018

 


Recent Filings from (NASDAQ: SIGA)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Registration of certain classes of securities 12(b) of the Securities Exchange Act
Filing Type: 8-A12BFiling Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Registration of certain classes of securities 12(b) of the Securities Exchange Act
Filing Type: 8-A12BFiling Source: edgar
Filing Date: March, 20 2018
Filing Type: CERTFiling Source: edgar
Filing Date: March, 20 2018
Filing Type: CERTFiling Source: edgar
Filing Date: March, 20 2018

 

 


Daily Technical Chart for (NASDAQ: SIGA)

Daily Technical Chart for (NASDAQ: SIGA)


Stay tuned for daily updates and more on (NASDAQ: SIGA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: SIGA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SIGA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SIGA and does not buy, sell, or trade any shares of SIGA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/